Rentosertib NCT05938920 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 15 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 2

Clinical phase

Completed

Recruitment status

not reported

Planned enrollment

2024-08-08

Primary-completion proxy

Executive view

NCT05938920 evaluates Rentosertib in Idiopathic Pulmonary Fibrosis. The disclosed sponsor is InSilico Medicine Hong Kong Ltd., the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is Percentage of Participants Who Had at Least 1 Treatment-emergent Adverse Event (TEAE), assessed over From first dose of study drug until end of study (EOS) visit i.e. up to 13 weeks (+10 days).

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT05938920 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Idiopathic Pulmonary Fibrosis landscape. Drug & Asset MCP drug_fetch was queried for Rentosertib, while Company & Deal Intelligence MCP organization_fetch was queried for InSilico Medicine Hong Kong Ltd..

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT05938920	Rentosertib	Phase 2 / Completed	InSilico Medicine Hong Kong Ltd.	China	Percentage of Participants Who Had at Least 1 Treatment-emergent Adverse Event (TEAE) From first dose of study drug until end of study (EOS) visit i.e. up…	2024-08-08
NCT06181370	AGMB-447	Phase 1 / Completed	AgomAb Therapeutics NV	United Kingdom	Number of participants with adverse events From Screening Through Study Completion, up to 8 Weeks	2026-04-29
NCT06160440	Sufenidone	Phase 1 / Completed	Guangzhou Jiayue Pharmaceutical Technology Co., Ltd.	China	Incidence and severity of adverse events and serious adverse events related drug. Evaluations will be conducted for up to 7 days after first administra…	2021-09-23
NCT06135363	Sufenidone	Phase 1 / Completed	Guangzhou Jiayue Pharmaceutical Technology Co., Ltd.	China	Incidence and severity of adverse events and serious adverse events related drug. From baseline to 7 days	2023-01-14
NCT06132256	Axatilimab-csfr	Phase 2 / Active, not recruiting	Syndax Pharmaceuticals, Inc.	Canada, South Korea, Romania, Belgium, Czechia, Taiwan Province, Poland, United Kingdom, Italy, France, Australia, Germany, Spain	Annualized rate of decline in morning pre-dose trough forced vital capacity (FVC) (milliliter [mL]) Baseline through Week 26	2026-09-01

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT05938920 is a Phase 2, completed study with not reported planned participants. Allocation is Randomized, masking is Double, and the intervention model is Parallel Assignment.

The primary endpoint is “Percentage of Participants Who Had at Least 1 Treatment-emergent Adverse Event (TEAE)” over “From first dose of study drug until end of study (EOS) visit i.e. up to 13 weeks (+10 days).” The retrieved endpoint description is: TEAEs were either events with start date on or after the start of the Treatment Period and up to 17 days after EOT (end of treatment), or events with start date prior to the start of the Treatment Period whose severity worsened on or after the start of the Treatment Period and up to 17 days after EOT. CTCAE=Common Terminology Criteria for Adverse Events.

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

0 recent result records were selected as contextual evidence for Idiopathic Pulmonary Fibrosis. These records do not establish direct evidence for NCT05938920 unless the registration number matches.

Indexed evidence status

No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Rentosertib is indexed as Small molecule drug with TNIK biology and a global stage of Phase 3. The asset profile lists InSilico Medicine Hong Kong Ltd. as an originator or developer.

InSilico Medicine Hong Kong Ltd. is indexed in an unreported country with the website http://www.insilico.com. Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases. The record lists 47 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Rentosertib is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT05938920
Protocol source: https://clinicaltrials.gov/study/NCT05938920
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 15 October 2026.

Rentosertib in Idiopathic Pulmonary Fibrosis is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Percentage of Participants Who Had at Least 1 Treatment-emergent Adverse Event (TEAE) and 2024-08-08 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP